The role of antiviral drugs in the treatment of dengue fever has been limited, but is currently widely studied. Focusing on the natural characteristics of dengue, this acute febrile illness can be ...

The possibility of treatment of dengue via antiviral drugs is still under investigation. Dengue has become a widespread infection over the past few year, extending from endemic to nonendemic areas.

Island Pharmaceuticals has commenced its phase 2b clinical trial of lead drug ISLA-101 – for potentially treating dengue ...

According to the World Health Organization (WHO), there are about 390 million dengue infections globally in a year, with more ...

Stockhead’s Fraser Palamara sits down with Island Pharmaceuticals (ASX:ILA)  CEO and managing director David Foster to get the short end of the long story on the company’s latest news.

Infections have increased dramatically over the past two years while, at the same time, developers of anti-dengue drugs and vaccines have abandoned their research and development efforts.